Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

550 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Eikelboom JW, et al. Among authors: hohnloser sh. Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747. Epub 2011 May 16. Circulation. 2011. PMID: 21576658 Clinical Trial.
Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention.
Crystal E, Lamy A, Connolly SJ, Kleine P, Hohnloser SH, Semelhago L, Abouzhar L, Cybulsky I, Shragge B, Teoh K, Lonn E, Sawchuk C, Oezaslan F; Left Atrial Appendage Occlusion Study. Crystal E, et al. Among authors: hohnloser sh. Am Heart J. 2003 Jan;145(1):174-8. doi: 10.1067/mhj.2003.44. Am Heart J. 2003. PMID: 12514671 Clinical Trial.
Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.
Dorian P, Borggrefe M, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, van der Laan M, Holroyde MJ, Singer I, Pratt CM; SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators. Dorian P, et al. Among authors: hohnloser sh. Circulation. 2004 Dec 14;110(24):3646-54. doi: 10.1161/01.CIR.0000149240.98971.A8. Epub 2004 Nov 8. Circulation. 2004. PMID: 15533855 Clinical Trial.
Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke.
Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH, Cybulsky I, Abouzahr L, Sawchuck C, Carroll S, Morillo C, Kleine P, Chu V, Lonn E, Connolly SJ. Healey JS, et al. Among authors: hohnloser sh. Am Heart J. 2005 Aug;150(2):288-93. doi: 10.1016/j.ahj.2004.09.054. Am Heart J. 2005. PMID: 16086933 Clinical Trial.
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Connolly SJ, et al. Among authors: hohnloser sh. JAMA. 2006 Jan 11;295(2):165-71. doi: 10.1001/jama.295.2.165. JAMA. 2006. PMID: 16403928 Clinical Trial.
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
ACTIVE Writing Group of the ACTIVE Investigators; Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. ACTIVE Writing Group of the ACTIVE Investigators, et al. Lancet. 2006 Jun 10;367(9526):1903-12. doi: 10.1016/S0140-6736(06)68845-4. Lancet. 2006. PMID: 16765759 Clinical Trial.
Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.
Active Steering Committee; ACTIVE Investigators; Connolly S, Yusuf S, Budaj A, Camm J, Chrolavicius S, Commerford PJ, Flather M, Fox KA, Hart R, Hohnloser S, Joyner C, Pfeffer M, Anand I, Arthur H, Avezum A, Bethala-Sithya M, Blumenthal M, Ceremuzynski L, De Caterina R, Diaz R, Flaker G, Frangin G, Franzosi MG, Gaudin C, Golitsyn S, Goldhaber S, Granger C, Halon D, Hermosillo A, Hunt D, Jansky P, Karatzas N, Keltai M, Lanas F, Lau CP, Le Heuzey JY, Lewis BS, Morais J, Morillo C, Oto A, Paolasso E, Peters RJ, Pfisterer M, Piegas L, Pipillis T, Proste C, Sitkei E, Swedberg K, Synhorst D, Talajic M, Trégou V, Valentin V, van Mieghem W, Weintraub W, Varigos J. Active Steering Committee, et al. Am Heart J. 2006 Jun;151(6):1187-93. doi: 10.1016/j.ahj.2005.06.026. Am Heart J. 2006. PMID: 16781218 Clinical Trial.
550 results